Rydapt And Alunbrig Approvals Headline Good Week For Targeted Oncologics At US FDA

After almost 20 years, targeted therapy for oncology is still producing breakthroughs. This week saw two breakthrough-designated novel kinase inhibitor approvals, Novartis' Rydapt (midostaurin) and Takeda's Alunbrig (brigatinib), and breakthrough status for Pfizer's next-generation candidate lorlatinib.

Immunotherapy is enjoying its moment as the next big thing in oncology, but a burst of recent FDA actions highlight how the last big thing – targeted therapy – is still going strong.

Molecularly targeted therapy for cancer has been on the market for two decades, starting with monoclonal antibodies like Genentech...